Abstract: The aim of this research is to develop a human/murine chimeric Fab antibody which neutralizes the anthrax toxin, protective antigen (PA). The chimeric Fab was constructed using variable regions of murine anti-PA monoclonal antibody in combination with constant regions of human IgG. The chimeric PA6-Fab was expressed in E. coli. BL21 and evaluated by ELISA and co-immunoprecipitation- mass spectra. The potency of PA6-Fab to neutralize LeTx was examined in J774A.1 cell viability in vitro and in Fisher 344 rats in vivo. The PA6-Fab did not have domain similarity corresponding to the current anti PA mAbs, but specifically bound to anthrax PA at an affinity of 1.76 nM, and was able to neutralize LeTx in vitro and protected 56.9 % cells ...
Anthrax vaccines primarily relying only on protective antigen (PA), the cell binding component in an...
Abstract Background Disease caused by Bacillus anthracis is often accompanied by high mortality prim...
Recombinant proteins have made a surge in therapeutics for a variety of applications. Recently, mon...
The aim of this research is to develop a human/murine chimeric Fab antibody which neutralizes the an...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
IntroductionBacillus anthracis is the causative agent for the lethal disease anthrax, primarily affe...
Anthrax has long been considered the most probable bioweapon-induced disease. The pro-tective antige...
Protective antigen (PA), one of the components of the anthrax toxin, is the major component of human...
International audienceProtective antigen (PA) is central to the action of the lethal and edema toxin...
The unpredictable nature of bioterrorism and the absence of real-time detection systems have highlig...
Protective Antigen (PA) is the receptor binding subunit common to both Lethal (LT) and Edema (ET) to...
Bacillus anthracis is the etiological agent of anthrax. Although anthrax is primarily an epizootic d...
Several studies have demonstrated that the passive transfer of protective antigen (PA)-neutralizing ...
A panel of human anti-anthrax protective antigen IgG1 monoclonal antibodies were evaluated to determ...
Anthrax is an acute disease caused by the bacterium Bacillus anthracis, and is a potential biowarfar...
Anthrax vaccines primarily relying only on protective antigen (PA), the cell binding component in an...
Abstract Background Disease caused by Bacillus anthracis is often accompanied by high mortality prim...
Recombinant proteins have made a surge in therapeutics for a variety of applications. Recently, mon...
The aim of this research is to develop a human/murine chimeric Fab antibody which neutralizes the an...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
IntroductionBacillus anthracis is the causative agent for the lethal disease anthrax, primarily affe...
Anthrax has long been considered the most probable bioweapon-induced disease. The pro-tective antige...
Protective antigen (PA), one of the components of the anthrax toxin, is the major component of human...
International audienceProtective antigen (PA) is central to the action of the lethal and edema toxin...
The unpredictable nature of bioterrorism and the absence of real-time detection systems have highlig...
Protective Antigen (PA) is the receptor binding subunit common to both Lethal (LT) and Edema (ET) to...
Bacillus anthracis is the etiological agent of anthrax. Although anthrax is primarily an epizootic d...
Several studies have demonstrated that the passive transfer of protective antigen (PA)-neutralizing ...
A panel of human anti-anthrax protective antigen IgG1 monoclonal antibodies were evaluated to determ...
Anthrax is an acute disease caused by the bacterium Bacillus anthracis, and is a potential biowarfar...
Anthrax vaccines primarily relying only on protective antigen (PA), the cell binding component in an...
Abstract Background Disease caused by Bacillus anthracis is often accompanied by high mortality prim...
Recombinant proteins have made a surge in therapeutics for a variety of applications. Recently, mon...